PhoreMost is pioneering new technologies to help create treatments for diseases which were previously considered ‘undruggable’.
Through its next-generation screening platforms such as SITESEEKER® and GlueSEEKER, PhoreMost is able to identify the best new targets for future therapies, particularly in oncology and in Targeted Protein Degradation, a technique for dealing with proteins that are causing diseases.
Through this innovative approach PhoreMost aims to expand the number of diseases that can respond to treatment, enabling the discovery of next-generation therapies.
By doing so, it is creating more effective and targeted medicines for patients, increasing treatment options for cancer and other diseases with limited therapies.
“The depth and breadth of Cambridge science are unparalleled, in tune with the disruptive and multidisciplinary nature of successful startups today.”
Unlocking new possibilities in drug development
PhoreMost, a spin-out from the University of Cambridge’s MRC Cancer Unit, was founded by Professor Ashok Venkitaraman, Dr Grahame Mckenzie, and Dr Chris Torrance. This innovative company aims to develop drugs for targets previously considered ‘undruggable’, bringing more effective, targeted medicines to patients.
At the heart of PhoreMost’s strategy is its phenotypic screening platform, SITESEEKER®. This technology identifies promising new targets for future therapies and determines how to effectively drug them.
In 2018, PhoreMost completed an £11 million Series A funding round, boosting their drug discovery efforts and expanding their SITESEEKER® platform. This seed funding round was led by Cambridge Enterprise Ventures, along with other key investors.
They have since gone on to complete a £33 million ($46 million) Series B funding round in 2021. This investment supports the progression of their PLK1 program for brain cancer treatment and advances their pipeline of novel therapies in oncology and diseases of aging.
Image credits: iStock
